Eli Lilly & Co.’s Mounjaro helped kids as young as 10 control their blood sugar and lose weight in a study that may give ...

The U.S. FDA has issued separate warning letters to Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) regarding claims made about ...

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro ...

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat ...

Lots of research suggests such medications must be used indefinitely to maintain weight loss and related health benefits. But ...

GLP-1 medications like Ozempic show promise for multiple health conditions, as experts explore microdosing benefits for blood ...

Demand for Eli Lilly’s LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years, both drugs ...

In a revealing preclinical study, the weight-loss drug tirzepatide—already known for fighting obesity and diabetes—unexpectedly slowed the growth of breast cancer tumors in obese mice. Researchers ...

How should those struggling to reach a healthy weight decide which weight loss intervention is right for them? ABC News looked at three options: lifestyle changes, bariatric surgery and the new ...